TP53 and chronic kidney disease: The percentage of BM-MSCs positive for senescence markers p16Ink4a, phospho-p53, SA-β-gal (senescence-associated-β-galactosidase), and 53BP1 (p53-binding protein) was lower in metformin-treated compared to control untreated CKD-MSCs, and the SASP was also reduced (Kim et al., 2021).